mRNA Cancer Vaccine Clinical Trial Landscape

What Is an mRNA Cancer Vaccine?

mRNA cancer vaccines are therapeutic immunotherapies — they don't prevent cancer, they train the immune system to recognize and destroy existing tumor cells. The mRNA encodes tumor-specific antigens (proteins found on cancer cells but not healthy tissue); once injected and taken up by dendritic cells, the mRNA is translated into protein fragments that are presented to T cells, generating a cytotoxic anti-tumor immune response.

Two strategic approaches dominate the field:

• Individualized neoantigen vaccines — The patient's tumor is biopsied and sequenced. An algorithm identifies somatic mutations that are likely to generate immunogenic peptides (neoantigens). A custom mRNA encoding 20-34 of those neoantigens is manufactured in 6-8 weeks and injected into the same patient. Each dose is unique — maximum specificity, but complex manufacturing and logistical requirements.
• Shared antigen vaccines — A fixed mRNA sequence encoding antigens common to a tumor type (KRAS mutations in pancreatic cancer, cancer-testis antigens like NY-ESO-1 and MAGE-A3 in melanoma) is manufactured at scale and administered off-the-shelf. Faster to deploy and cheaper to produce, but less targeted than individualized approaches.

Both approaches are combined with checkpoint inhibitors (pembrolizumab, atezolizumab) in virtually every Phase 2/3 trial — the hypothesis being that checkpoint blockade removes immunosuppressive brakes while the vaccine provides the antigen-specific "steering wheel" to direct the immune response at tumor cells.

The Leading mRNA Cancer Vaccine Programs

mRNA-4157 / V940 (Moderna + Merck) — Individualized Neoantigen

The most clinically advanced mRNA cancer vaccine in 2026. Each dose encodes up to 34 neoantigens specific to the individual patient's tumor mutations, identified via whole-exome sequencing and bioinformatic neoantigen prediction. Delivered via lipid nanoparticle (LNP) injection, manufactured in approximately 6 weeks from biopsy.

Key data: KEYNOTE-942 Phase 2b trial (n=157, resected Stage III/IV melanoma) — mRNA-4157 + pembrolizumab vs. pembrolizumab alone — showed 44% reduction in risk of recurrence or death (HR 0.561, p=0.0266). At 3-year follow-up, 74.8% of vaccine-treated patients remained recurrence-free vs. 55.6% in the pembrolizumab-only arm.

Active Phase 3 programs:

• V940-001 / KEYNOTE-A83: Resected high-risk Stage III/IV melanoma + pembrolizumab vs. pembrolizumab (Phase 3 confirmatory)
• Resected NSCLC (Stage IB-IIIA): mRNA-4157 + pembrolizumab adjuvant vs. pembrolizumab — multiple Phase 3 trials in progress
• Bladder cancer, renal cell carcinoma, and head and neck squamous cell carcinoma Phase 2/3 expansion programs

mRNA-5671 / V941 (Moderna + Merck) — KRAS Shared Antigen

A fixed-sequence mRNA vaccine encoding four of the most common KRAS oncogenic mutations: G12D (~45% of PDAC), G12V (~30% of PDAC), G12C (~13% of NSCLC), and G13D. These mutations are tumor-specific (the wild-type KRAS protein is ubiquitous, but the mutant peptides are foreign to the immune system) — making them theoretically ideal shared antigens.

Unlike individualized vaccines, mRNA-5671 requires no patient-specific manufacturing: it can be administered within days of diagnosis. Phase 1 was conducted in KRAS-mutant solid tumors (NSCLC, CRC, PDAC) in combination with pembrolizumab. Phase 1 immunogenicity results were not uniformly positive — KRAS neoepitopes appear less immunogenic than expected in some patients, a key challenge for shared antigen approaches. Moderna's primary development focus has shifted to the individualized platform (mRNA-4157), but shared antigen approaches for PDAC remain an area of continued investigation across the field.

BNT122 / Autogene Cevumeran (BioNTech + Genentech/Roche) — Individualized Neoantigen

BioNTech's individualized neoantigen cancer vaccine, developed in partnership with Genentech (Roche). Uses BioNTech's proprietary mRNA backbone and LNP delivery system — the same platform validated by the COVID-19 vaccine at scale.

Pivotal result in pancreatic cancer (PDAC): Phase 1/2 pilot study in resected pancreatic cancer patients (n=16 treated). Among the 8 patients who mounted a vaccine-induced neoantigen-specific T cell response, median recurrence-free survival was not reached at 18 months; among the 8 non-responders, median RFS was 13.4 months. This immunogenicity-stratified outcome analysis, published in Nature (2023), provided the first clinical evidence that mRNA cancer vaccines can drive durable anti-tumor immunity in PDAC — historically among the least immunogenic tumor types. A randomized Phase 2 trial (BNT122-01) is now enrolling resected PDAC patients.

BNT111 — FixVac Fixed Antigen Vaccine (BioNTech) — Melanoma

BNT111 (FixVac) is a fixed-sequence mRNA cancer vaccine encoding four melanoma-associated shared antigens: NY-ESO-1 (cancer-testis antigen), MAGE-A3 (cancer-testis antigen), tyrosinase (melanocyte differentiation antigen), and TPTE (transmembrane phosphatase). These antigens are expressed in the majority of melanomas but absent or minimally expressed in most normal adult tissues.

BNT111 is in Phase 2 testing in unresectable Stage III/IV melanoma, both as monotherapy in checkpoint inhibitor-refractory patients and in combination with cemiplimab (Regeneron) in checkpoint-naive patients. Phase 1 data showed tumor-antigen-specific T cell responses in ~75% of patients, with objective responses (partial + complete) in checkpoint-refractory patients — encouraging for a population with few options.

BNT116 — mRNA Lung Cancer Vaccine (BioNTech) — NSCLC

BNT116 is a fixed-sequence mRNA vaccine targeting six lung cancer-associated shared antigens selected for expression in NSCLC tumors across histologies. Unlike BNT111 (melanoma-specific antigens), BNT116's targets span squamous and adenocarcinoma subtypes.

Phase 1/2 (LuCa-MERIT trial) testing in combination with pembrolizumab in NSCLC. Early proof-of-concept study; preliminary immunogenicity and safety data expected in 2025-2026. Targeting NSCLC with a shared antigen approach is differentiated — most vaccine development has focused on melanoma (highly immunogenic) or PDAC (high unmet need). NSCLC sits in between: KRAS-mutant NSCLC overlaps with mRNA-5671's target population.

Key mRNA Cancer Vaccine Trials (2026)

Competitive Landscape by Tumor Type

Melanoma — Most Advanced

Melanoma is the most advanced indication for mRNA cancer vaccines. Its high tumor mutational burden (TMB) makes it rich in neoantigens — and its well-established responsiveness to checkpoint inhibitors creates an ideal combination backbone. mRNA-4157 + pembrolizumab has the most robust Phase 2 data (KEYNOTE-942). BNT111 in combination with cemiplimab addresses the checkpoint-refractory population. The key open question is whether Phase 3 data will confirm the Phase 2b RFS benefit — a positive Phase 3 readout for mRNA-4157 would likely trigger broad adoption across oncology and accelerate the field significantly.

Pancreatic Cancer (PDAC) — Highest Unmet Need

PDAC is the most compelling rationale for mRNA cancer vaccines — a disease where checkpoint immunotherapy has historically failed as monotherapy (low TMB, immunosuppressive tumor microenvironment), but where individualized neoantigen approaches may overcome the immunosuppression by generating high-avidity T cell responses to personalized tumor antigens. BNT122's Nature publication remains the key proof-of-concept. mRNA-5671 targets KRAS mutations common in PDAC. The BNT122 Phase 2 randomized trial in resected PDAC is the most watched study in this space — a positive signal would validate the neoantigen approach in the most immunotherapy-resistant major tumor type.

NSCLC — Expanding Rapidly

NSCLC is the next large opportunity. mRNA-4157 is now in Phase 3 adjuvant NSCLC following the melanoma proof of concept. BNT116 (shared antigen) is in Phase 1/2. KRAS G12C and G12D mutations in NSCLC create overlap with the small molecule KRAS inhibitor field — an open question is whether combining mRNA vaccines with KRAS inhibitors (which increase KRAS peptide presentation) could produce synergy. No clinical data on this combination yet as of 2026.

Colorectal Cancer

Microsatellite-stable (MSS) colorectal cancer — the majority of CRC — is poorly responsive to checkpoint immunotherapy. MSS CRC has moderate TMB but a highly immunosuppressive TME. Individualized neoantigen vaccines represent a potential approach to break immune tolerance. mRNA-4157 is in early expansion, and BNT122 data in PDAC has spurred interest in CRC. Multiple smaller programs are ongoing.

Key Sponsors

Manufacturing and Delivery — Key Differentiators

The individualized neoantigen approach requires manufacturing a custom product for each patient — a significant logistical and technical challenge:

• Turnaround time: Moderna's mRNA-4157 platform requires ~6 weeks from tumor biopsy receipt to patient dose. BioNTech's BNT122 has a similar manufacturing window. This means patients must be treated in an adjuvant setting (after resection, before relapse) — not a viable approach for rapidly progressing metastatic disease.
• Lipid nanoparticle (LNP) delivery: Both Moderna and BioNTech use LNP formulations validated at clinical scale by COVID-19 vaccines. LNPs are injected subcutaneously or intramuscularly and taken up by local antigen-presenting cells (APCs), particularly dendritic cells that migrate to lymph nodes and prime T cell responses.
• Adjuvants: mRNA vaccines deliver their own innate immune stimulation via the mRNA molecule itself (pattern recognition receptors recognize foreign RNA), but optimizing the innate immune response without excessive toxicity remains an active manufacturing challenge.
• Cold chain: mRNA is inherently unstable; vaccines require ultra-cold storage similar to COVID-19 mRNA vaccines. Clinical operations in oncology trials must manage this logistical complexity at cancer centers.

Frequently asked questions